Union Budget 2024: Three Cancer Medicines Exempted from Customs Duty

In a significant move to support cancer patients, Finance Minister Nirmala Sitharaman announced that three cancer treatment medicines will be exempted from customs duty1. This decision was made during the 50th GST Council meeting held on July 11, 20232.

Details of the Exemption

The exemption applies to three specific cancer medicines, which are crucial for the treatment of various types of cancer. This initiative aims to reduce the financial burden on patients and make these life-saving drugs more accessible3. The medicines included in this exemption are Dinutuximab (Quarziba), a drug used for treating neuroblastoma, and two other essential cancer treatment drugs.

Impact on Patients

The exemption from customs duty is expected to significantly lower the cost of these medicines, making them more affordable for patients. This move is part of the government’s broader effort to improve healthcare accessibility and affordability in India. By reducing the cost of essential cancer treatments, the government aims to provide better support to patients and their families, ensuring that financial constraints do not hinder access to necessary medical care.

In conclusion, the exemption of customs duty on three cancer medicines is a commendable step towards enhancing healthcare accessibility and supporting cancer patients in India. This decision reflects the government’s commitment to improving the quality of life for those battling cancer.